# Patent

## Title
Botulinum neurotoxin antigenic compositions and methods

## Abstract

Methods and compositions pertaining to botulinum neurotoxin (BoNT) light chain epitopes are provided. In particular, the methods and compositions relate to the use of real and mimetic BoNT light chain epitopes for generating an immune response in a subject, and for immunization against BoNT toxicity. Methods and compositions for detecting, isolating, and purifying BoNT epitopes and anti-BoNT antibodies are also provided.

## Background
CLAIM OF PRIORITY
This application is the U.S. National Stage of PCT/US2011/025482, filed Feb. 18, 2011, which claims priority to U.S. Provisional Application 61/338,477, filed Feb. 20, 2010, the entire contents of which are hereby incorporated by reference.
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jul. 31, 2012, is named 09952301.txt and is 59,774 bytes in size.


FIELD OF INVENTION
The present technology relates to antigenic compositions of botulinum neurotoxin (BoNT), and methods for detecting, isolating, or purifying BoNT epitopes and anti-BoNT antibodies. Method of using such epitopes and antibodies are also disclosed.
BACKGROUND
The following description is provided to assist the understanding of the reader. None of the information provided or references cited is admitted to be prior art to the present disclosure.
The seven serologically distinct botulinum neurotoxins produced by Clostridium botulinum, Clostridium argentiensis, and Clostridium baratti, (BoNT/A, /B, /C, /D, /E, /F, /G) are some of the most potent toxins known to mankind. These homologous toxins specifically target neurons and act through the interruption of neurotransmission. This interruption results in muscle paralysis, which in severe cases of intoxication leads to death from asphyxiation in humans and animals. Human botulism is typically caused by serotypes A, B, E, and occasionally F. Serotypes C and D cause toxicity only in non-human animals.
A single molecule of each toxin possesses three functional domains: receptor-recognition, transport and catalytic. The catalytic domains are Zn2+ metalloproteases that recognize and selectively cleave proteins involved in targeting of presynaptic vesicles and their fusion with the neuronal plasma membrane, in this way neurotoxins block neurotransmitter release into the synaptic cleft. Although there is a certain degree of homology between different clostridial neurotoxins, their catalytic domains recognize different substrates: BoNT/B, /D, /F and /G cleave synaptobrevin 2; BoNT/A, /C and /E cleave synaptosomal-associated protein of 25 kDa (SNAP25); BoNT/C cleaves syntaxin.
Botulinum neurotoxins are synthesized as single polypeptides approximately 1500 amino acids in length (Mr ̃150 kDa), and then cleaved into heavy and light chains (Mr ̃100 kDa, Mr ̃50 kDa), which are held together by a disulfide bond. The light chain corresponds to the catalytic domain while heavy chains carry the receptor-recognition and transport domains, and are responsible for transport of corresponding light chains into the cytosol of neuronal cells.
Currently, botulinum neurotoxins are viewed as potent biological warfare agents. At the same time, botulinum neurotoxins of serotypes A and B are extensively used in medicine as drugs for the treatment of strabismus, blepharospasms, migraines and many other neurological conditions. The toxins are also commonly used as cosmetic agents.
In recent years, several researchers have used a series of synthetic BoNT/A peptides to map epitopes recognized by antisera from several species, including humans, and peptide displays of BoNT/A to map epitopes recognized by monoclonal antibodies. Others have reported epitopes recognized by neutralizing anti-BoNT antibodies. Thus far, however, epitope mapping efforts have focused on the heavy chains of botulinum neurotoxins.
SUMMARY
In one embodiment, the present disclosure relates to an antigenic composition comprising: a carrier peptide and at least one epitope, wherein the carrier peptide is selected from the group consisting of Receptor Associated Protein (RAP), Clostridium perfringens α-toxin, and cholera toxin subunit B, and wherein the carrier peptide and the epitope comprise a fusion protein. Additionally or alternatively, in some embodiments, the epitope comprises a real or mimetic botulinum neurotoxin (BoNT) epitope. In some embodiments, the epitope is capable of eliciting an immune response in a human or animal subject. Additionally or alternatively, in some embodiments, the fusion protein specifically binds to an anti-BoNT antibody. In another embodiment, the real or mimetic epitope includes one or more of the sequences given in FIG. 3 or Tables 3-5.
In some embodiments, the fusion protein is encoded by a polynucleotide. Additionally or alternatively, in some embodiments, the polynucleotide is provided, in an expression vector. In another embodiment, the expression vector is selected from the group consisting of a plasmid DNA, a viral vector, a bacterial vector, and a mammalian vector. Typically, the vector is capable of autonomous replication in a host cell. In another embodiment, the vector is capable of integrating into the genome of the host.
In some embodiments, the present disclosure relates to an antigenic composition comprising multiple real and/or multiple mimetic BoNT epitopes. In some embodiments, at each epitope is capable of individually eliciting an immune response in a human or animal subject. Additionally or alternatively, in some embodiments, administering a therapeutically effective amount of the composition to the subject elicits multiple immune responses directed to multiple epitopes. In some embodiments, each epitope specifically binds to an anti-BoNT antibody.
In some embodiments, the present disclosure relates to a method for producing an antigenic composition comprising (a) expressing in a host cell a fusion protein comprising a carrier peptide and at least one epitope, wherein the carrier peptide is selected from the group consisting of Receptor Associated Protein (RAP), Clostridium perfringens α-toxin, and cholera toxin subunit B. In some embodiments, the epitope of the fusion protein is antigenic. In further embodiments, the methods include the step of isolating the fusion protein from the host. In some embodiments, the epitope comprises a real or mimetic botulinum neurotoxin (BoNT) epitope. In some embodiments, the epitope is capable of eliciting an immune response in a human or animal subject. In some embodiments, the real or mimetic epitope is selected from the epitopes shown in FIG. 3 or Tables 3-5. In another embodiment, the fusion protein is expressed in the host cell from an expression vector. In another embodiment, the expression vector is selected from the group consisting of a plasmid DNA, a viral vector, a bacterial vector, and a mammalian vector. Typically, the vector is capable of autonomous replication in a host cell. In another embodiment, the vector is capable of integrating into the genome of the host cell. In another embodiment, the fusion protein comprises a carrier peptide and multiple real and/or multiple mimetic BoNT epitopes. In some embodiments, the epitopes are capable of individually eliciting an immune response in a human or animal subject.
In one embodiment, the present disclosure relates to a method for isolating a real or mimetic BoNT epitope from a host cell comprising: expressing the epitope as a fusion protein with a Receptor Associated Protein (RAP) carrier peptide, wherein the carrier peptide enhances the solubility of said epitope. In some embodiments, the host cell is E. coli. In some embodiments, the fusion protein is isolated from solution.
In one embodiment, the present disclosure relates to a method for isolating a real or mimetic BoNT epitope from a host cell comprising: expressing the epitope as a fusion protein with a Clostridium perfringens α-toxin carrier peptide, wherein the fusion protein is secreted by the host cell into the culture medium. In some embodiments, the host cell is E. coli. In some embodiments, the fusion protein is isolated from the culture medium.
In one embodiment, methods are provided for isolating or purifying anti-BoNT antibodies from a sample comprising: (a) contacting the sample with a biochemically effective amount of a BoNT epitope-containing composition under conditions conducive to specific epitope-antibody binding; (b) removing non-specifically bound contaminants; (c) altering conditions to release bound antibodies; and (d) recovering the released antibodies.
In one embodiment, methods are provided for detecting the presence of anti-BoNT antibodies in a sample comprising: (a) contacting the sample with a diagnostically effective amount of a BoNT epitope-containing composition under conditions conducive to specific epitope-antibody binding, and (b) detecting the antibodies.
In one embodiment, methods are provided for diagnosing the exposure of a human or animal subject to BoNT comprising: (a) contacting a biological sample front the subject with a diagnostically effective amount of a composition comprising at least one BoNT epitope under conditions conducive to specific epitope-antibody binding. In some embodiments, the methods include the step of contacting the sample with an appropriate secondary detection reagent. In one embodiment, the sample is a cell, tissue, or bodily fluid. In some embodiments, the BoNT epitope is fused to a carrier protein.
In one embodiment, the present disclosure relates to a method of immunizing a human or animal subject against BoNT toxicity comprising: administering to the subject a therapeutically effective amount of a BoNT epitope-containing composition. In some embodiments, the composition elicits an immune response directed to the BoNT epitope component of the composition.
In one embodiment, the present disclosure relates to a method of decreasing the likelihood of BoNT toxicity in a human or animal subject comprising: administering to the subject a therapeutically effective amount of a BoNT epitope-containing composition wherein the composition elicits an immune response directed to the BoNT epitope component of the composition. In another embodiment, the subject is administered a composition containing nucleic acids encoding BoNT epitopes.
In one embodiment, the present disclosure provides a method of eliciting an immune response in a human or animal subject comprising: administering to the subject a therapeutically effective amount of a BoNT epitope-containing composition wherein the composition elicits an immune response directed to the BoNT component of the composition.
In one embodiment, the present provides a composition for isolating, purifying, or detecting Receptor Associated Protein (RAP) comprising a polymer resin coupled to a plurality of peptides, wherein the peptides possess an affinity for specific binding to RAP.
In one embodiment, the present disclosure provides a method for isolating, purifying, or detecting RAP proteins, fragments, or derivatives thereof in a sample comprising: (a) contacting said sample with a polymer resin coupled to a plurality of peptides, wherein said peptides specifically bind to RAP, under conditions conducive to specific peptide-RAP binding; (b) removing non-specifically bound contaminants; (c) altering conditions to promote RAP release; and (d) recovering the released RAP.
In one embodiment, the present disclosure provides to a method of purifying anti-BoNT antibodies from a sample comprising: (a) contacting the sample with a polymer resin coupled to a fusion protein comprising a RAP carrier peptide and at least one real or mimetic BoNT epitope, under conditions conducive to specific epitope-antibody binding; (b) removing non-specifically bound contaminants; (c) altering conditions to release bound antibodies, and (d) recovering the released antibodies. In one embodiment, the BoNT epitopes are selected from the epitopes shown in FIG. 3 or Tables 3-5.



BRIEF DESCRIPTION OF THE FIGURES
FIG. 1. Real epitope map of BoNT/A light chain. The full-length BoNT/A sequence is shown in plain type. Four real epitopes were identified through screening of the BoNT/A peptide expression library with rabbit anti-BoNT/A antisera, designated Adel1, Adel2, Adel3, and Adel4. For each of Adel1, Adel2, and Adel4, multiple immunoreactive clones were isolated, designated-1, -2, etc. The real epitopes are defined as the region of overlap between the clones. FIG. 1 discloses SEQ ID NOS 92-101, respectively, in order of appearance.
FIG. 2. Antigenic properties of identified BoNT/A real epitopes. Identified BoNT/A real epitopes were expressed in E. coli as HisbioRAP fusion proteins. Bacterial lysates were purified on Ni-Sepharose and the products resolved by SDS-PAGE. Proteins were visualized by Coomassie staining (A) and Western blotting (B-C). Blots were probed with rabbit anti-BoNT/A whole serum (B) or a fraction of the serum affinity purified, on HisbioRAP-del4-coupled resin. Samples were loaded in the following order: (1) BoNT/Adel2; (2) BoNT/Adel1-1(3) HisbioRAP control (4) BoNT/AB-L; (5) pre-stained molecular weight markers; (6) BoNT/Adel4; (7) BoNT/Adel1; (8) HisbioRAP-random peptide. BoNT/AB-L (lane 5) is a derivative of BoNT/A-L in which the BoNT/A-del4 region has been substituted with that of BoNT/B.
FIG. 3. Alignment of BoNT real epitopes. Sequence of the del1, del2, del3, and del4 real epitopes is well conserved across the BoNT serotypes an in the related tetanus toxin. The Zn domain is the most highly conserved across the toxins. This region was not identified as a real epitope in the screening of BoNT/A-L and was used as a negative control for anti-BoNT blotting. These sequences were used to test the cross-reactivity of rabbit anti-sera FIG. 3 discloses SEQ ID NOS 102-133, respectively, in order of appearance.
FIG. 4. Cross-reactivity of BoNT antisera with the BoNT/A, /B, and /F del1 epitopes BoNT/A, /B, and /F del1 peptides were expressed in E. coli as HisbioRAP fusion proteins. Bacterial lysates were purified on Ni-Sepharose and the products resolved by SDS-PAGE. Proteins were visualized by Coomassie staining (A) and Western blotting (B-D). Blots were probed with rabbit anti-BoNT/F (B), anti-BoNT/B (C), or anti-BoNT/A (D). Samples were loaded in the following order: (1) BoNT/A-Zn; (2) BoNT/FAdel1; (3) BoNT/BAdel1; (4) BoNT/Fdel1; (5) BoNT/Bdel1; (6) BoNT/Adel1, (7) BoNT/AB-L; (8) pre-stained molecular markers, BoNT/AB-L is a BoNT/A-L derivative in which the C-terminal region has been substituted with the corresponding region of BoNT/B-L.
FIG. 5 Cross-reactivity of anti-BoNT antibodies raised against a BoNT/FBAdel1 mosaic peptide. BoNT/B-L, /A-L, /A-CH, /A-Zn, and /FBAdel1 peptides were expressed in E. coli as HisbioRAP fusion proteins. Bacterial lysates were purified on Ni-Sepharose and the products resolved by SDS-PAGE. Proteins were visualized by Coomassie staining (A) and Western blotting (B-D). Blots were probed with rabbit anti-BoNT/A (B), anti-BoNT/B (C), or the sera of mice immunized with a BoNT/FBAdel1 peptide, Samples were loaded in the following order: (1) tetanus toxin light chain; (2) BoNT/B-L; (3) BoNT/A-L; (4) GFP-BoNT/A-CH; (5) BoNT/A-Zn; (6) BoNT/FBAdel1; (7) pre-stained molecular weight markers.
FIG. 6. Use of mimetic BoNT epitopes to affinity purify anti-BoNT/A antibodies. BoNT/A heavy and light chains were expressed in E. coli. BoNT mimetic epitopes AIII-1, AIII-L1, and AIII-26 were expressed in E. coli as HisbioRAF fusion proteins. Bacterial extracts were resolved by SDS-PAGE and proteins were visualized by Western Blotting with rabbit anti-BoNT/A serum (A) or fractions of the scram affinity purified on resin coupled to RAP fusions of mimetic epitopes AIII-1 (B), AIII-L1 (C), or AIII-1 (D-E). Samples were loaded in the following order: (1), pre-stained molecular weight markers; (2) full-length BoNT/A heavy chain; (3) full-length BoNT/A light chain; (4) HisbioRAP-BoNT/AIII-26; (5) HisbioRAP-BoNT/AIII-1; (6) HisbioRAP-BoNT/AIII-L1.
FIG. 7. Amino Acid Sequences of Exemplary Fusion Proteins. Amino acid sequences of HisbioRAP (upper panel) and C. perfringens □-toxin (second panel) fusion proteins bearing three BoNT real epitope peptides in series. The del1 epitope of BoNT serotypes F, B, and A are highlighted. FIG. 7 discloses SEQ ID NOS 134-137, respectively, in order of appearance.



DETAILED DESCRIPTION
In practicing the present disclosure, many conventional techniques in cell biology, molecular biology, protein biochemistry, immunology, and bacteriology are used. These techniques are well-known in the art and are provided in any number of available publications, including Current Protocols in Molecular Biology, Vols. I-III, Ausubel, Ed, (1997); Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Ed. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989).
Certain terms used herein are defined below. Unless defined otherwise, all technical and scientific terms used herein have the same general meaning as commonly understood by one skilled in the art.
As used herein, the singular forms “a,” “an,” and “the” include plural referents unless the content clearly indicates otherwise. For example, reference to “a cell” includes a combination of two or more cells, etc.
As used herein, “administration” of a composition to a subject includes any route of delivering the compound to the subject to perform its intended function. Administration can be carried out by any suitable route including oral, intranasal, parenteral (intravenous, intramuscular, intraperitoneal, or subcutaneous), or topical. Administration includes self-administration and administration by another.
As used herein, the terms “antigen” and “antigenic” refer to molecules with the capacity to be recognized by an antibody or otherwise act as a member of an antibody-ligand pair. “Specific binding” refers to the interaction of an antigen with the variable regions of immunoglobulin heavy and light chains. Antibody-antigen binding may occur in vivo or in vitro. The skilled artisan will understand that macromolecules, including proteins, nucleic acids, fatty acids, lipids, lipopolysaccharides and polysaccharides have the potential to act as an antigen. The skilled artisan will further understand that nucleic acids encoding a protein with the potential to act as an antibody ligand necessarily encodes an antigen. The artisan will further understand that antigens are not limited to fall-length proteins, but can also include partial amino acid sequences. Moreover, sequences from different sources may be combined to generate mosaic antigens, depending on the specific intended use. In some embodiments, the mosaic antigen will include epitopes derived from different proteins. In some embodiments, the mosaic antigen will include epitopes derived from the same protein. The term “antigenic” is an adjectival reference to molecules having the properties of an antigen.
As used herein, the term “epitope” refers to that portion of a molecule that forms a site specifically recognized by an antibody or immune cell. A protein epitope may comprise amino acid residues directly involved in antibody binding, as well as residues not directly involved in binding that are nonetheless included in the antibody-epi tope footprint and excluded from the solvent surface. Epitopes may derive from a variety of physical characteristics of a protein, including primary, secondary, and tertiary amino acid structure, and amino acid/protein charge. Epitopes present within a molecule are referred to as “real epitopes.” Real epitopes encompass wild-type sequences and variants of wild-type sequences. Real epitopes may exist within a wild-type protein, a naturally occurring variant of a wild-type protein, or an engineered variant of a wild-type protein. The term “mimetic epitope” refers to a molecule unrelated to a given real epitope that nonetheless specifically binds to antibodies that recognize the real epitope. Epitopes may be isolated, purified, or otherwise prepared by those skilled in the art. They may be obtained from natural sources including cells and tissues, or they may be isolated from host cells expressing a recombinant form of the epitope.
As used herein, “effective amount” refers to a quantity sufficient to achieve a desired effect. In the context of therapeutic or prophylactic applications, the effective amount will depend on the type and severity of the condition at issue and on the characteristics of the individual subject, such as general health, age, sex, body weight, and tolerance to pharmaceutical compositions. In the context of an antigenic composition, in some embodiments, an effective amount is an amount sufficient to result in a protective response against a pathogen. In other embodiments, an effective amount of an antigenic composition is an amount sufficient to result in antibody generation against the antigen. With respect to antigenic compositions, in some embodiments, an effective amount will depend on the intended use, the degree of immunogenicity of a particular antigenic compound, and the health/responsiveness of the subject's immune system, in addition to the factors described above. The skilled artisan will be able to determine appropriate amounts depending on these and other factors. In the case of a biochemical application, in some embodiments, an effective amount will depend on the size and nature of the sample in question. It will also depend on the nature and sensitivity of the methods in use. The skilled artisan will be able to determine the effective amount based on these and other considerations.
As used herein, the term “polymer resin” refers to resins, such as, but not limited to polysaccharide polymers such as agarose and SepharoseTM. The skilled artisan will understand that proteins may be covalently attached to the resin using methods well known in the art, including but not limited to cyanogen bromide activation, reductive animation of aldehydes, and the addition of iodoacetyl functional groups. The skilled artisan will further understand that functional equivalents of polysaccharide polymers may also be to immobilize proteins.
As used herein, the term “BoNT” refers to any of the seven serologically distinct botulinum neurotoxins produced by Clostridium botulinum, Clostridium argentiensis, and Clostridium baratti. Individual serotypes are referred to as BoNT/A, BoNT/B, BoNT/C, BoNT/D, BoNT/E, BoNT/F, and BoNT/G. Exemplary, non-limiting nucleic acid sequences of BoNT/A, /B, /C, /D, /E, /F, and /G are found in GenBank Accession numbers DQ409059, FM865705, AB200364, NZ ACSJ101000015, AM695754, X81714, and X74162, respectively. Exemplary, non-limiting amino acid sequences of BoNT/A, /B, /C, /D, /E, /F, and /G are found in GenBank Accession numbers ABD65472, CAR97779, BAD90572, ZP 04863672, CAM91137, CAA57358, and CAA52275, respectively. Exemplary, non-limiting nucleic and amino acid sequences of C. tetani tetanus toxin are found in GenBank Accession numbers AF154828 and AAF73267, respectively. As used herein, the term “BoNT/A-L” refers to the full-length botulinum neurotoxin A light chain. As used herein, the term “BoNT/B-L” refers to the full-length botulinum neurotoxin B light chain.
As used herein, the term “anti-BoNT antibody” refers to an antibody capable of specifically binding to BoNT. As used herein, an antibody includes a polyclonal antibody, a monoclonal antibody, and also refers to functional fragments (e.g., fragments which bind an antigen/epitope), such as Fv, Fab, Fe and CDRs.
As used herein, the term “carrier” or “carrier peptide” refers to a protein expressed as an in-frame fusion with a protein of interest to facilitate isolating, purifying, identifying or otherwise manipulating the protein or peptide of interest. The term encompasses proteins conventionally used as epitope tags, including but not limited to the receptor associated protein (“RAP”), Myc, green fluorescent protein (“GFP”), hemagglutinin (“HA”), FLAG, poly-histidine, thioredoxin, cholera toxin B subunit, E. coli cholera-like toxin, Halo-tag, and biotin. In some embodiments, the carrier comprises the combination of three tags comprising His-bio-RAP. The term also encompasses fragments or portions of these proteins, variant of these proteins, and peptides not conventionally used as epitope tags. The skilled artisan will understand that the term encompasses any proteins or peptides used to facilitate isolating, purifying, identifying, or otherwise manipulating a protein of interest.
As used herein, the term “Clostridium perfringens α-toxin” refers to C. perfringens phospholipase C. One exemplary α-toxin is shown by GenBank Accession number ABA64004.
As used herein, the term “Receptor Associated Protein (RAP)” Homo sapiens alpha-2-macroglobulin receptor-associated protein. One exemplary RAP protein is shown by GenBank Accession number AAA51553.
As used herein, the terms “immunogen” and “immunogenic” refer to molecules with the capacity to elicit an immune response. The response may involve antibody production or the activation of immune cells. The response may occur in vivo or in vitro. The skilled artisan will understand that a variety of macromolecule, including proteins, have the potential to be immunogenic. The skilled artisan will further understand that nucleic acids encoding a molecule capable of eliciting an immune response necessarily encodes an immunogen. The artisan will further understand that immunogens are not limited to full-length molecules, but may include partial amino acid sequences (e.g., epitopes). Moreover, sequences from different sources may be combined to generate mosaic immunogens, depending on the specific intended use.
As used herein, the terms “isolate” and “purify” refer to processes of obtaining a biological substance that is substantially free of material and/or contaminants normally found in its natural environment (e.g. from the cells or tissues from which a protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized chemically.
As used herein, the term the terms “polypeptide,” “peptide,” and “protein” are used interchangeable to mean a polymer comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds (i.e., peptide isosteres). Polypeptides may include amino acids other than the naturally-occurring amino acids, as well as amino acid analogs and mimetics prepared by techniques that are well known in the art. The skilled artisan will understand that polypeptides, peptides, and proteins may be obtained in a variety of ways including isolation from cells and tissues expressing the protein endogenously, isolation from cell or tissues expressing a recombinant form of the molecule, or synthesized chemically.
As used herein, the term “sample” includes but is not limited to whole or fractionated prokaryotic or eukaryotic cells, whole or fractionated bodily tissue, whole or fractionated bodily fluid such as blood, lymph, mucus, tears, saliva, sputum, CSF, urine, or artificial bodily fluid. Samples also include stool, hair and/or sloughed cells.
As used herein, the term “subject” refers to a member of any vertebrate species. The methods of the presently disclosed subject matter are particularly useful for warm-blooded vertebrates. In some embodiments, the subject is avian and includes domestic (e.g., chicken, turkey) and wild bird species. In some embodiments, subjects include mammals such as humans, as well as those mammals of importance due to being endangered, of economic importance (animals raised on farms for consumption by humans) and/or social importance (animals kept as pets or in zoos) to humans. In particular embodiments, the subject is a human. In other embodiments, the subject is not human.
I. Epitopes
A. General
Disclosed herein are methods and compositions for the identification and isolation of polypeptide epitopes. In some embodiments, the epitopes are real epitopes. In other embodiments, the epitopes are mimetic epi topes. Mimetic epitopes are typically unrelated to a given real epitope but nonetheless specifically bind to antibodies that recognize the real epitope. In some embodiments, a mimetic epitope has a different amino acid sequence, secondary, tertiary and/or quaternary structure than a counterpart real epitope.
In some embodiments, epitopes are used singly, while in other embodiments, combinations of epitopes are used. Regarding combinations of epitopes, in some embodiments, the epitopes are presented as a collection of individual molecules for use; additionally, or alternatively, the combination of comprises a series of epitopes within a single polypeptide. In some embodiments, a combination of epitopes includes a variety of different real epitopes, a variety of different mimetic epitopes, or a combination of real and mimetic epitopes. Different epitopes used in combination include, but are not limited to, epitopes from different regions of a particular antigen and epitopes from different antigens. For example, in some embodiments, epitopes from different serotypes are combined; additionally or alternatively, in other embodiments, epitopes from different bacterial, fungal, viral, or other infectious agent are combined. By way of example, but not by way of limitation, in some embodiments, epitopes of 2, 3, 4, 5, 6 or 7 different serotypes BoNT are combined. Additionally, or alternatively, in some embodiments, epitopes for tetanus toxin, are combined with one or more BoNT serotype specific epitopes. In still other embodiments, epitopes for HIV and/or HCV, pneumonia are combined. The skilled artisan will understand that the disclosure is not limited to specific combinations of epi topes, and that any number of combinations of epitopes can be created to address a set of diseases or infections likely to occur together in a subject. By way of example, and not by way of limitation, the combination of epitopes can be administered to a subject to generate an immune response thereby preventing, treating, alleviating or decreasing the likelihood of disease or infection.
In some embodiments, a composition including multiple epitopes is provided. In some embodiments, each epitope is capable of individually eliciting an immune response in a human or animal subject. Additionally or alternatively, in some embodiments, administering a therapeutically effective amount of the composition to a subject elicits multiple immune responses directed to multiple epitopes. In some embodiments, each epitope specifically binds to an anti-BoNT antibody, and each epitope is capable of individually eliciting an immune response in a human or animal subject.
In some embodiments, the epitopes are linked to one or more carrier proteins, and in some embodiments, the carrier protein is used to aid in the identification, isolation and/or characterization of the epitopes. In some embodiments, the carrier protein is generally non-antigenic and/or non-immunogenic (e.g., it does not elicit a detectable immune response when administered to a subject). Additionally or alternatively, in some embodiments, the carrier protein enhances the solubility of the epitope; in other embodiments, the carrier protein facilitates excretion of the epitope from a cell (e.g., a host cell) and into the cell culture medium. In some embodiments, the epitope comprises a series of epitopes within a single polypeptide fused to a carrier protein.
In some embodiments, the epitopes are derived from botulinum neurotoxin, and in particular, from the botulinum neurotoxin light chains (BoNT). Exemplary BoNT real and mimetic epitopes are presented in FIG. 3 and Tables 3-5.
B. Methods of Generating and Identification of Real Epitopes
Real epitopes can be identified using bacterial expression systems well known in the art. For example, an expression library can be generated from a polynucleotide encoding the full-length protein. Random peptides derived from the full length protein can then be expressed in a host cell (e.g., E. coli) as fusion protein with a carrier. In some embodiments, carriers include one or more of a polyhistidine repeat (His), biotin (bio) and human Receptor Associated Protein (RAP). The carrier can be linked to the N-terminus or the C-terminus of the peptides. Bacterial colonies can then be replica plated and probed for recognition by an anti-antisera derived from the full-length protein. Immunoreactive peptides can then be sequenced and mapped to the full-length protein to identify real epitopes.
By way of example, but not by way of limitation, BoNT real epitopes (FIG. 3) were identified using a bacterial expression system well known in the art. An expression library was generated from a polynucleotide encoding the full-length BoNT/A light chain. The amino acid sequence of the BoNT/A light chain is shown in FIG. 1. Random peptides derived from the BoNT/A light chain were expressed in E. coli as fusion proteins bearing three N-terminal tags: a polyhistidine repeat (His), a biotinylatable peptide (bio), and human Receptor Associated Protein (RAP). Bacterial colonies were replica plated and probed for recognition by an anti-BoNT antisera. Immunoreactive peptides were sequenced and mapped to the light chain. The locations and sequences of the BoNT light chain real epitopes are given in FIG. 1.
C. Methods of Generating and Identification of Mimetic Epitopes
In some embodiments, mimetic epitopes are identified using phage display techniques well known in the art. For example, multiple random peptide display libraries are subjected to multiple rounds of bio-panning with an antibody specific for a molecule of interest. Immunoreactive particles can then be isolated and amplified.
Recombinant proteins encompassing the real and mimetic epitopes can be prepared using standard techniques well known in the art. For example, polynucleotides encoding carrier-epitope fusions can be cloned into plasmid vectors under the control of an inducible promoter and transformed into E. coli. Expression of the fusion protein construct can be induced under standard conditions and the fusion protein recovered from bacterial cell lysates using techniques routine in the art.
By way of example but not by way of limitation, BoNT mimetic epitopes were identified using phage display techniques well known in the art. Two random peptide display libraries were subjected to multiple rounds of biopanning with rabbit anti-BoNT antisera. Immunoreactive particles were isolated and amplified.
D. Methods of Expressing Epitopes and Preparing Antigenic Compositions
The present disclosure provides methods for preparing antigenic compositions, in some embodiments, the methods include transfecting or transforming a host cell with an expression vector encoding one or more epitopes, or one or more epitopes linked to a carrier protein, expressing the epitope or epitope fusion and isolating the epitope or epitope fusion so expressed. The skilled artisan will appreciate that a variety of tools and methods may be used to prepare compositions comprising real or mimetic epi topes. Any number of expression vectors may be used to produce fusion proteins. Exemplary vectors include, but are not limited to plasmid DNA vectors, viral vectors, bacterial vectors and mammalian vectors. Non-limiting examples of specific vectors known in the art include pUC, pET and Flexi vectors and derivatives thereof. In some embodiments, the fusion protein is encoded by a transposable element which integrates into a host genome.
Any number of carrier proteins may be used to facilitate expression, identification and manipulation of the fusion proteins, including but not limited to Myc, GFP, HA, FLAG, poly-histidine, thioredoxin, cholera toxin B subunit, E. coli cholera-like toxin, and Halo-tag and RAP.
Likewise, any number of bacterial or non-bacterial host cells may be used to express the proteins, including but not limited to bacteria such as E. coli, Erwinia carotovora, and Bacillus subtilis, eukaryotic cells such as yeast, plant, mammalian, and insect cells. Conventional molecular biology methods known in the art may be used to build the necessary constructs (e.g., expression vectors), including but not limited to PCR amplification of endogenous or recombinant DNA, direct cloning of endogenous DNA, oligonucleotide synthesis, or gene synthesis.
In addition, conventional biochemistry methods known in the art may be used to recover the fusion protein from bacterial or non-bacterial cell lysates. Cell-free translation systems may be used to generate the fusion protein and may be preferable under some circumstances. Examples of cell free translation systems include but are not limited to those that utilize reticulocyte lysate and wheat germ extracts. Detection of the epitope or related antibodies may be accomplished by a number of techniques, including but not limited to enzyme-linked immunoabsorbent assays (ELISA) and immunoblotting.
In some embodiments, an antigenic composition includes a fusion protein bearing a single real or mimetic epitope. In other embodiments, the antigenic compound comprises a fusion protein bearing multiple real or multiple mimetic epitopes. In yet another embodiment, the antigenic compound comprises a fusion protein bearing a combination of real and mimetic epitopes. Additionally or alternatively, in some embodiments, the antigenic compound includes multiple real and/or multiple mimetic epitopes derived from multiple pathogens.
In one embodiment, the fusion peptide is specifically recognized by an antibody known to bind the antigen from which the epitope was derived or modeled. In another embodiment, the real or mimetic epitope of the fusion peptide is capable of eliciting and immune response in a human or animal subject.
For example, in some embodiments, recombinant proteins encompassing BoNT real and mimetic epitopes can prepared using standard techniques well known in the art. Polynucleotides encoding carrier-BoNT fusions can be cloned into plasmid vectors under the control of an inducible promoter and transformed into a host cell such as E. coli. Expression of the fusion protein construct can be induced under standard conditions and the fusion protein recovered from bacterial cell lysates using techniques routine in the art. In some embodiments, the epitope includes one or more real or mimetic BoNT epitopes. Exemplary BoNT real and mimetic epitopes are presented in FIG. 3 and Tables 3-5.
In some embodiments, a method for producing an antigenic composition includes (a) expressing in a host cell a fusion protein comprising a carrier peptide and at least one epitope, wherein the carrier peptide is selected, from the group consisting of Receptor Associated Protein (RAP) and Clostridium perfringens α-toxin; and (b) isolating the fusion protein produced by the host. Additionally or alternatively, in some embodiments, the epitope includes a real or mimetic BoNT epitope. In some embodiments, the epitope is capable of eliciting an immune response in a human or animal subject. In some embodiments, the real or mimetic epitope is selected from the group consisting the epitopes shown in FIG. 3 and Tables 3-5. In some embodiments, the fusion protein is expressed in the host cell from an expression vector, and in some embodiments, the expression vector is selected from the group consisting of a plasmid DNA, a viral vector, a bacterial vector, a mammalian vector, and a vector capable of integrating into the genome of the host cell. Typically, the vector is capable of autonomous replication in a host cell. In some embodiments, the fusion protein includes a carrier peptide and multiple real and/or multiple mimetic BoNT epitopes, and in some embodiments, the real or mimetic epitopes are selected from the group consisting the epitopes shown in FIG. 3 and Tables 3-5.
II. Method for Isolating Fusion Proteins and RAP
A. RAP Fusions
Disclosed herein are methods and compositions useful for the isolation of RAP fusion proteins. In some embodiments, fusion of RAP, a RAP fragment or a RAP variant with a protein of interest enhances the solubility of the fusion protein, thereby facilitating isolation of the fusion via methods known in the art. For example, full-length RAP, the N-terminal half of RAP, and the C-terminal half of the RAP, can independently enhance the solubility of fusion peptides.
In the methods, a polypeptide of interest (e.g., one or more epitope) is fused to RAP, a RAP fragment, or RAP derivative or variant. The fusion protein is expressed in a host cell (e.g., in E. coli), wherein the RAP carrier protein enhances the aqueous solubility of the fusion protein. In one embodiment, the method includes the use of a RAP carrier peptide to enhance the solubility of any protein of interest.
In some embodiments, a RAP fusion protein comprising RAP, a RAP fragment or a RAP variant fused to a protein of interest, is affinity purified from a sample by contacting the sample with a heparin coupled to a polymer resin (RAP is a natural heparin ligand).
In some embodiments, the protein of interest is one or more real or mimetic BoNT epitopes. Exemplary BoNT real and mimetic epitopes are presented in FIG. 3 and Tables 3-5. Exemplary BoNT fusions are provided in FIG. 7.
For example, in some embodiments, a method is provide for isolating a real or mimetic BoNT epitope from a host cell comprising: expressing the epitope as a fusion protein with a Receptor Associated Protein (RAP) carrier peptide, wherein the carrier peptide enhances the solubility of said epitope; and isolating the fusion protein from solution. In some embodiments, the protein of interest is one or more real or mimetic BoNT epitopes. In some embodiments, the epitopes are selected from the BoNT real and mimetic epitopes presented in FIG. 3 and Tables 3-5. In some embodiments, the fusions are those shown in FIG. 7.
1. Isolation of RAP Proteins
In some embodiments, methods are provided for isolating, purifying, or detecting Receptor Associated Protein (RAP). In some embodiments, the methods include providing a polymer resin coupled to a plurality of peptides, wherein the peptides specifically bind to RAP.
In some embodiments, methods for isolating, purifying, or detecting Receptor Associated Protein (RAP) in a sample are provided. In some embodiments, the methods include: (a) contacting the sample with a polymer resin coupled to a plurality of peptides, wherein said peptides specifically bind to RAP, under conditions conducive to specific peptide-RAP binding; (b) removing non-specifically bound contaminants; (c) altering conditions to promote RAP release; and (d) recovering the released RAP.
In some embodiments, the plurality of peptides includes RAP-binding peptides isolated by phage display. In some embodiments, the plurality of peptides include the peptides listed in Table 6. In some embodiments, heparin is coupled to the resin.
B. Other Fusions
In some embodiments, the fusion protein includes a carrier or tag protein other than RAP. By way of example, but not by way of limitation, the carrier protein may include one or more of conventionally used as epitope tags such as Myc, GFP, HA, FLAG, poly-histidine, thioredoxin, cholera toxin B subunit, E. coli cholera-like toxin, Halo-tag, and biotin. In some embodiments, the carrier comprises the combination of three tags comprising His-bio-RAP. In some embodiments, purification methods include the use of nickel-binding peptides shown in Table 7. In some embodiments, purification methods may include the use of streptavidin and/or Strep A coupled to a polymer resin for use in affinity chromatography. In some embodiments, purification methods include the use of streptavidin-binding peptides shown in Table 8.
In some embodiments, the protein of interest is one or more real or mimetic BoNT epitopes. Exemplary BoNT real and mimetic epitopes are presented in FIG. 3 and Tables 3-5. Exemplary multiple epitope fusions are shown in FIG. 7.
III. Method for Isolating C. perfringens α-Toxin Fusion Proteins E. coli 
Disclosed herein are methods and compositions useful for the isolation of C. perfringens α-toxin fusion proteins. In some embodiments, the fusion includes α-toxin, an α-toxin fragment, or an α-toxin derivative or variant, and at least one fusion partner. In some embodiments, the fusion partner is one or more epitopes. In general, the methods include expressing the α-toxin fusion in E. coli, wherein the α-toxin carrier protein promotes secretion of the fusion protein into the culture medium. In one embodiment, α-toxin carrier peptide is used to promote the secretion of a fusion protein into a bacterial culture medium, thereby facilitating isolation of the fusion protein.
In some embodiments, the fusion partner is one or more real or mimetic BoNT epitopes. Exemplary BoNT real and mimetic epitopes are presented in FIG. 3 and Tables 3-5.
In some embodiments, a method is provided for isolating a real or mimetic BoNT epitope from host cell comprising: expressing the epitope as a fusion protein with a Clostridium perfringens α-toxin carrier peptide, wherein the fusion protein is secreted by E. coli into the culture medium; and isolating the fusion protein from the culture medium. In some embodiments, the epitopes are selected from the BoNT real and mimetic epitopes presented in FIG. 3 and Tables 3-5. In some embodiments, the fusions are those shown in FIG. 7.
IV. Methods for Isolating, Purifying, or Detecting Antibodies
In one embodiment, the present disclosure provides methods for isolating or purifying antibodies in a sample. In some embodiments, the method comprises contacting the sample with a biochemically effective amount of a composition comprising one or more real and/or mimetic epitopes under conditions conducive to specific antibody-antigen binding, providing awash step in which non-specifically bound contaminants are removed, altering conditions to promote the release of bound antibodies, and recovering released antibodies. In some embodiments the sample comprises a cell, tissue, bodily fluid, or fraction thereof. In some embodiments the sample comprises an experimental sample. In some embodiments, experimental samples comprise lysates from cultured cells or fractions thereof tissue homogenates and/or bodily fluids, etc. from experimental animals or fractions thereof. In other embodiments the sample comprises a patient sample.
In some embodiments, the antibodies are BoNT antibodies and the epitope comprises one or more real or mimetic BoNT epitopes. In some embodiments, the BoNT epitope is selected, from the epitopes of FIG. 3 and Tables 3-5. Additionally or alternatively, in some embodiments, the BoNT epitope is present as a fusion with a carrier protein.
In some embodiments, the methods related to the detection and/or quantification of antibodies in a sample comprising contacting a sample with a biochemically effective amount of a composition comprising a real or mimetic epitope under conditions conducive to specific antibody-antigen binding, providing a wash step in which non-specifically bound contaminants are removed, and detecting the presence and/or amount of bound antibody. In some embodiments, the methods encompass the use of secondary detection reagents including but not limited to species-specific secondary antibodies coupled, to a fluorescent or enzymatic label. In some embodiments the sample comprises a cell, tissue, or bodily fluid or fraction thereof. In some embodiments the sample comprises an experimental sample. In some embodiments, experimental samples comprise lysates from cultured cells or fractions thereof, tissue homogenates and/or bodily fluids, etc. from experimental animals or fractions thereof. In other embodiments the sample comprises a patient sample.
In some embodiments, the antibodies are BoNT antibodies and the epitope comprises one or more real or mimetic BoNT epitopes. In some embodiments, the BoNT epitope is selected, from the epitopes of FIG. 3 and Tables 3-5. Additionally or alternatively, in some embodiments, the BoNT epitope is present as a fusion with a carrier protein.
In some embodiments, methods are provided for isolating or purifying anti-BoNT antibodies from a sample comprising: (a) contacting the sample with a biochemically effective amount of the composition comprising at least one BoNT epitope under conditions conducive to specific epitope-antibody binding; (b) removing non-specifically bound contaminants; (c) altering conditions to release bound antibodies; and (d) recovering the released antibodies.
In further embodiments, methods are provided for detecting, the presence of anti-BoNT antibodies in a sample comprising: (a) contacting the sample with a diagnostically effective amount of the composition comprising at least one BoNT epitope under conditions conducive to specific epitope-antibody binding, and (b) detecting the antibodies. In some embodiments, the BoNT epitope is selected, from the epitopes of FIG. 3 and Tables 3-5. Additionally, or alternatively, in some embodiments, the BoNT epitope is present as a fusion with a carrier protein.
In some embodiments, methods are provided for purifying anti-BoNT antibodies from a sample comprising: (a) contacting the sample with a polymer resin coupled to a fusion protein comprising a RAP carrier peptide and at least one real or mimetic BoNT epitope, under conditions conducive to specific epitope-antibody binding; (b) removing non-specifically bound contaminants; (c) altering conditions to release bound antibodies, and (d) recovering the released antibodies. In some embodiments, the BoNT epitope is selected from the epitopes of FIG. 3 and Tables 3-5. Additionally, or alternatively, in some embodiments, the BoNT epitope is present as a fusion with a carrier protein.
V. Method of Diagnosing
In some embodiments, the methods relate to diagnosing the exposure of a human or animal subject to a pathogen, comprising detecting the presence of antibodies that specifically bind the pathogen, in a sample derived from the subject. For example, in some embodiments, the method encompasses contacting the sample with a polymer resin coupled to a fusion protein, comprising one or more carrier proteins (e.g., RAP) and one or more real or mimetic epitopes under conditions conducive to specific antibody-antigen binding, providing a wash step to remove non-specifically bound contaminants, altering conditions to release bound antibodies, and recovering released, antibodies, in other embodiments, the fusion protein is linked to a solid support and enzyme-linked immunosorbent assay is used to detect the antibodies. For example, in one embodiment, the sample is contacted with the fusion protein linked to the solid support under conditions conducive to specific antibody-antigen binding, a wash step is provided to remove non-specifically bound contaminants, and a second fusion protein is provided to identify the bound antibody. In some embodiments, secondary reagents are used to aid in the identification and/or quantification of the bound antibody.
In some embodiments, the pathogen comprises one or more of Clostridium botulinum, Clostridium argentiensis, and Clostridium baratti, and the RAP fusion comprises RAP, a RAP fragment or RAP variant fused to one or more real or mimetic BoNT epitopes. Exemplary BoNT real and mimetic epitopes are presented in FIG. 3 and Tables 3-5.
In some embodiments, methods are provided for diagnosing the exposure of a human or animal subject to BoNT comprising: (a) contacting a biological sample from the subject with a diagnostically effective amount of the composition comprising at least one BoNT epitope, under conditions conducive to specific epitope-antibody binding, and (b) contacting the sample with an appropriate secondary detection reagent. In some embodiments, the sample is a cell, tissue, or bodily fluid. In some embodiments, the BoNT epitope is selected from the epitopes of FIG. 3 and Tables 3-5. Additionally or alternatively, in some embodiments, the BoNT epitope is present as a fusion with a carrier protein.
VI. Methods of Eliciting an Immune Response in a Human or Animal Subject
The present disclosure provides methods for eliciting an immune response in a human or animal subject comprising administering to the subject a therapeutically effective amount of a composition comprising a real or mimetic epitope, wherein the composition elicits an immune response directed to the epitope. In some embodiments, the antigenic composition comprises a fusion protein bearing a single real or mimetic epitope. In another embodiment, the antigenic composition comprises a fusion protein bearing multiple real or multiple mimetic epitopes. In yet another embodiment, the antigenic composition comprises a fusion protein bearing a combination of real and mimetic epitopes. Additionally or alternatively, in some embodiments, the antigenic composition includes multiple real or multiple mimetic epitopes derived from multiple pathogens. In another embodiment, the antigenic composition includes a combination of real and mimetic epitopes derived from multiple pathogens.
In some embodiments, the methods include immunizing a human or animal subject against BoNT toxicity. Additionally or alternatively, in some embodiments, the methods further include decreasing the likelihood or severity of BoNT toxicity in a human or animal subject.
In some embodiments, the animal to be immunized includes livestock, such as animals used for human consumption. In some embodiments, the animal includes domestic birds (e.g., chickens, turkeys) or wild birds. In other embodiments, the animal to be vaccinated includes cattle, sheep, goats, pigs, dogs and cats. In other embodiments, the animal to be vaccinated does not include humans. In alternative embodiments, the animal to be vaccinated is a human.
In some embodiments, methods of immunizing a human or animal subject against BoNT toxicity are provided. In some embodiments, the methods include administering to the subject a therapeutically effective amount of the composition comprising at least one BoNT epitope, wherein the composition elicits an immune response directed to the BoNT component of the composition. In some embodiments, the BoNT epitope is selected from the epitopes of FIG. 3 and Tables 3-5. Additionally or alternatively, in some embodiments, the BoNT epitope is present as a fusion with a carrier protein.
In some embodiments, method of decreasing the likelihood of BoNT toxicity in a human or animal subject are provided. In some embodiments, the methods include administering to the subject a therapeutically effective amount of a composition comprising at least one BoNT epitope, wherein the composition elicits an immune response directed to the BoNT component of the composition. In some embodiments, the BoNT epitope is selected, from the epitopes of FIG. 3 and Tables 3-5. Additionally or alternatively, in some embodiments, the BoNT epitope is present as a fusion with a carrier protein.
In some embodiments, a method of eliciting an immune response in a human or animal subject is provided. In some embodiments, the method includes administering to the subject a therapeutically effective amount of the composition comprising at least one BoNT epitope, wherein the composition elicits an immune response directed to the BoNT component of the composition. In some embodiments, the BoNT epitope is selected from the epitopes of FIG. 3 and Tables 3-5. Additionally or alternatively, in some embodiments, the BoNT epitope is present as a fusion with a carrier protein.
A. Pharmaceutical Compositions Including One or More Real or Mimetic Epitopes
Disclosed herein are pharmaceutical compositions including one or more real or mimetic epitopes, useful for eliciting an immune response. Pharmaceutical compositions are typically formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral (e.g., intravenous, intradermal, intraperitoneal or subcutaneous, oral, inhalation, transdermal (topical), intraocular, iontophoretic, and transmucosal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic. For convenience of the patient or treating physician, the dosing formulation can be provided in a kit containing all necessary equipment (e.g., vials of drug, vials of diluent, syringes and needles) for a treatment course (e.g., multiple days of treatment).
Pharmaceutical compositions suitable for injectable use can include sterile aqueous solutions (where the components are water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, N.J.), or phosphate buffered saline (PBS). In all cases, a composition for parenteral administration must be sterile and should be fluid to the extent that easy syringability exists. It should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
Oral compositions generally include an inert diluent or an edible carrier. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. e.g., gelatin capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
For administration by inhalation, the compounds can be delivered in the form of an aerosol spray from a pressurized container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
B. Dosage of Pharmaceutical Composition Including One or More Real or Mimetic Epitopes
Dosage, toxicity and therapeutic efficacy of epitope-containing compositions described herein can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, for example, to determine the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. Compositions which exhibit high therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.
The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the methods, the therapeutically effective dose can be estimated initially from cell culture assays. A dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.
In some embodiments, an effective amount of an epitope sufficient for achieving a therapeutic or prophylactic effect, ranges from about 0.000001 mg per kilogram body weight per administration to about 10,000 mg per kilogram body weight per administration. Suitably, the dosage ranges are from about 0.0001 mg per kilogram body weight per administration to about 100 mg per kilogram body weight per administration. Administration can be provided as an initial dose, followed by one or more “booster” doses. Booster doses can be provided a day, two days, three days, a week, two weeks, three weeks, one, two, three, six or twelve months after an initial dose. In some embodiments, a booster dose is administered after an evaluation of the subject's antibody titer.
The skilled artisan will appreciate that certain factors may influence the dosage and timing required to effectively treat a subject, including but not limited to, the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of the therapeutic compositions described, herein can include a single treatment or a series of treatments.
VII. Method for Isolating Real or Mimetic RAP Binding Partners
In further embodiments, RAP, a RAP fragment or a RAP variant is coupled to a polymer resin and is used to isolate real or mimetic RAP binding partners generated by phage display. In some embodiments, the bound, real or mimetic RAP binding partner is eluted with heparin.
EXAMPLES
The present invention is further illustrated by the following examples, which should not be construed as limiting in any way,
Materials and Methods
Cells and Plasmids—
Recombinant DNAs were cloned and amplified using E. coli DH5αF′ cells. Fusion proteins were expressed in E. coli BL21(λDE3) cells. Plasmid pUCentryBoNT/A-L1 (unpublished) was used to generate the BoNT/A library. The plasmid carries the BoNT/A light chain coding sequence flanked by unique KpnI and XbaI sites on the 5′ end, and unique SalI and SacI sites on the 3′ end (5′-KpnI-XbaI-BoNT/A-L-SalI-SacI-3′). Fusion proteins bearing BoNT real or mimetic epitopes were expressed in plasmid pParaBAD-T7HisbioRAP2 (unpublished) under the control of a bacteriophage T7 promoter. Plasmid pETαtoxABglII1 (unpublished) encodes the C. perfringens α-toxin under the control of a bacteriophage T7 promoter. All vectors were constructed to carry similar polylinkers to allow for ease of subcloning.
Enzymes—
Restriction enzymes, T4 DNA-polymerase, S1 nuclease and rapid DNA ligation kits, were purchased from Fermentas Life Sciences.
Oligonucleotides—
Complementary oligonucleotide pairs encoding BoNT real epitopes are listed in Table 1. All were synthesized at GenScript Corporation. Fusion proteins bearing epitopes derived from these oligos were given “s” (synthetic) designation (Adel1s, Adel4s, Bdel1s, Fdel1s). Oligos were also used to generate mosaic peptides carrying multiple real epitopes in series (BA-del1s, FA-del1s, FBA-del1s).
Antibodies—
Rabbit antisera raised against BoNT/A, /B and /F were kindly provided by Dr. Vertiev (Russia). Purified rabbit anti-BoNT antibodies were purchased from Metabiologics Inc (Madison, Wis.).
Generation of a BoNT/A Expression Library—
Plasmid pUCentryBoNT/A-L1 was cut with KpnI and XbaI. Digestion with XbaI generated a 5′ overhang susceptible to degradation by Exonuclease III. Digestion with KpnI generated a 3′ overhang resistant to degradation by Exonuclease III. To generate a series of 5′ BoNT/A deletions, the linearized pUCentryBoNT/A-L1 was treated sequentially with Exonuclease III, S1 nuclease, and DNA ligase. To generate a series of 3′ cutbacks, the 5′ deletion library was digested with SalI and SacI, and then treated sequentially with Exonuclease III, S1 nuclease, and DNA ligase. The cutbacks were excised as EcoRI-XhoI fragments, isolated by gel electrophoresis, and subcloned into pParaBAD-HisbioRAP. The library consisted of 3×104 independent clones with an average BoNT/A fragment length of 75 base-pairs.
Screening of the BoNT/A Expression Library—
The BoNT expression library was grown on LB-agar plates supplemented with ampicillin. Colonies were replica plated and transferred to nitrocellulose for immunoblotting using methods standard in the art. Colonies were probed with rabbit anti-BoNT/A and an anti-rabbit HRP secondary antibody. Immunoreactivity was visualized with metal-enhanced DAB (Pierce).
Expression and Purification of Recombinant Proteins—
All bacterial cultures were grown at 37° C. to an absorbency of 0.5-0.6 (600 nm). Protein expression was induced by addition of isopropyl-β-D thiogalactoside. HisbioRAP cultures were transferred to 24° C. and induced for 16 hours. Bacteria were lysed by sonication and the recombinant proteins purified from the soluble fraction by affinity chromatography using Ni-NTA Superflow (Qiagen). Cultures expressing the α-toxin-BoNT/FRA-del1 fusion were induced for 90 minutes at 37° C. The fusion protein was purified from the culture media by ultrafiltration on PREP/SCALE-TFF Cartridge 30K (Millipore) and ion-exchange chromatography on HiTrapTM QFF (GE Healthcare).
Immunization BoNT Real Epitopes—
Six-to-eight-week-old female BALB/c mice were purchased from Harlan Laboratories, Inc. Mice were allowed a 1-week period of acclimatization and then vaccinated intraperitoneally or subcutaneously with HisbioRAP-BoNT/FBA-del1s (FIG. 7), formaldehyde-treated α-Tox-FBA-del1s (FIG. 7), or control in the presence of Freunds Complete and Freunds Incomplete adjuvants. Three rounds of immunization were performed two weeks apart with 10, 20 and 40 μg of antigen, respectively. Tail bleeds were drawn at 28 and 42 days post-immunization and screened by ELISA. Results are presented as fold increase in OD450 over pre-immune sera (Table 2).
Immunization with BoNT Mimetic Epitopes
Six-to-eight-week-old female BALB/c mice were purchased from Harlan Laboratories, Inc. Mice were allowed a 1-week period of acclimatization and then vaccinated intraperitoneally with 25 mg of HisbioRAP-BoNT/A-mimetic-8 at weeks 1, 3, and 4. The HisbioRAP-BoNT/A-mimetic-8 fusion protein bears eight BoNT/A mimetic epitopes in series: BoNT/AVII1-3, BoNT/AVII1-6, BoNT/AVII1-13, BoNT/AVII1-19, BoNT/AVII1-20, BoNT/AVII3-17, BoNT/AVII5-4, BoNT/AVII5-18 (shown in Table 3). Control mice were immunized with normal saline only. At week 5, mice were challenged with a dose of BoNT/A corresponding to 5× the LD50.
ELISA—
Diluted mouse sera were added to ELISA wells coated with α-Tox-FBAdel1s or HisbioRAP-FRAdel1s. Plates were incubated at 37° C. for 60 minutes, washed, and probed with goat anti-mouse HRP (Accurate Chemical) for 45 min at 37° C. Following a final wash, 200 μl of tetramethyl benzidine substrate was added to each well and incubated for 20 minutes. The reaction was terminated by the addition of H2SO4 to a final concentration of 0.2 N. Absorption was measured at 450 nm.
Western Blot—
Proteins were resolved on 4-10% SDS-PAGE gradient gels and transferred to PVDF (Millipore). Membranes were blocked with PBS, 0.1% Tween 20, 2% BSA and incubated with specified primary antibodies. Membranes were then probed with species-specific antibodies coupled to HRP and developed with metal enhanced DAB (Pierce).
Phage Display—
Phage display library Ph.D.-12TM (New England Biolabs) and phage display library MD12TM (Alpha Universe LLC) were used to isolate BoNT mimetic epitopes. Both libraries utilize filamentous phage M13 as a peptide carrier. Ph.D.-12TM peptides are exposed to the surface of the phage particle as fusion of protein III. MD12TM peptides are exposed as a fusion of protein VII.
BoNT mimetic epitopes were isolated from a random peptide display library using a modified biopanning protocol. Conventional biopanning utilizes a representative pool of recombinant particles (phages, cells or ribosomes), each member of which expresses a single species of fusion protein. The pool is incubated with an immobilized target molecule, and non-binding particles are washed away. Bound particles are then eluted and amplified. After several rounds of selection, even very rare binding events can be isolated and amplified.
In the modified protocol, a depletion step was included in which the peptide display library was incubated with pre-Immune rabbit sera. Non-specific antibody-display particle complexes were removed with Staphylococcal protein A and Streptococcal protein G. This step depleted the display library of non-specific interactors and ensured that probing the library with anti-BoNT antisera would yield only specific interactions. Following the depletion step, the display library was subjected to three rounds of biopanning with anti-BoNT targets. Random peptide libraries of BoNT/A, BoNT/B, and BoNT/E were screened with anti-BoNT/A, anti-BoNT/B, and anti-BoNT/E antisera, respectively.
Example 1
Identification of Real BoNT Epitopes
The BoNT/A expression library was screened for immunoreactivity with rabbit anti-BoNT/A (See Materials and Methods, supra). Four antigenic regions of the BoNT/A light chain were identified, designated real epitopes Adel1, Adel2, Adel3, and Adel4 (FIG. 1). Multiple positive clones were isolated for the del1, del2 and del4 regions, designated-1-2, etc. Analysis of the clones showed the real epitope to be the region of overlap (FIG. 1).
HisBioRAP fusion proteins bearing Adel1, Adel2, and Adel4 peptides were probed by western blot with anti-BoNT/A serum (FIG. 2B). A full-length serotype A/B hybrid (BoNT/AB-L) and the HisbioRAP carrier peptide were loaded as positive and negative controls, respectively. BoNT/AB-L is a derivative of BoNT/A-L, in which the Adel4 epitope has been substituted with that of BoNT serotype B (BoNT/B). Protein resolution was confirmed by Coomassie staining (FIG. 2A) and an identical blot was probed with the antiserum.
All BoNT derived fusions were detected by BoNT/A antisera, while the HisbioRap carrier protein was not (FIG. 2B). Thus, recognition of the BoNT/A fusion proteins by anti-BoNT/A antibodies is specific for the BoNT component of the proteins, and not the HisbioRAP carrier peptide.
While the native Adel3 epitope shows immunoreactivity with anti-BoNT/A serum (as in expression library screening), it is not reactive by Western blot (not shown). This suggests that unlike Adel1, Adel2, and Adel4, Adel3 likely encodes a structural epitope that does not withstand treatment with SDS. Detection of the Adel1, Adel2, and Adel4 peptides by western blot suggests that they generate linear epitopes.
Example 2
Isolation of Anti-BoNT/A Antibodies Specific for the Adel4 Epitope
HisbioRAP fusion proteins bearing Adel1, Adel2, and Adel4 peptides were probed by western blot with anti-BoNT/A serum purified against a HisbioRAP-BoNT/Adel4s fusion protein (FIG. 2C). BoNT/AB-L and the HisbioRAP carrier peptide were loaded as negative controls. Protein resolution was confirmed by Coomassie staining (FIG. 2A) and an identical blot was probed with the purified serum (FIG. 2C).
Of the BoNT-derived proteins loaded, only that bearing the Adel4 epitope was detected by the purified serum (FIG. 2C, lane 6). None of the other BoNT/A real epitopes were detected, nor was the full-length BoNT/AB-L hybrid (FIG. 2C).
These results illustrate several points. First, recombinant fusion proteins bearing BoNT real epitopes are effective tools for isolating anti-BoNT antibodies from whole serum. Second, BoNT epitopes within a given serotype are distinct from one another, with differing antibody specificities. For example, purified anti-Adel4 did not recognize Adel1 or Adel2 (FIG. 2C). Third, although the BoNT real epitopes are well conserved across the BoNT serotypes (FIG. 3), at least some are sufficiently distinct from one another to display differing antibody specificities. For example, purified anti-Adel4 did not recognize the Bdel4 epitope of the BoNT/AB-L fusion (FIG. 2C).
Example 3
Cross-Reactivity of BoNT Antisera with the BoNT/A, /B, and F/del1 Epitopes
HisbioRAP fusion proteins bearing the Adel1, Bdel1, and Fdel1 epitopes singly or in combination were probed by Western blot with rabbit antisera raised against BoNT/A, BoNT/B, or BoNT/F (FIG. 4B-D). BoNT/A-Zn was loaded as a negative control. Protein resolution was confirmed by Coomassie staining (FIG. 4A) and identical blots were probed with each antisera.
Each of the antisera tested demonstrated serotype specificity. Anti-BoNT/A recognized the Adel1 epitope when present singly, in combination with Bdel1 and Fdel1, and in the context of the full-length BoNT/AB-L hybrid protein (FIG. 4D). Anti-BoNT/A did not recognize the Bdel1 or Fdel1 epitopes (FIG. 4D). Anti-BoNT/B showed a similar degree of specificity, recognizing the Bdel1 epitope when present singly, in combination with the Adel1 and Fdel1 epitopes, and in the context of the full-length BoNT/AB-L hybrid protein (FIG. 4C). Anti-BoNT/B did not recognize the Adel1 or Fdel1 epitopes (FIG. 4C). Anti-BoNT/F recognized the Fdel1 epitope when present singly, in combination with the Adel1 and Bdel1 epitopes, and in the context of the full-length BoNT/AB-L hybrid protein (FIG. 4B). However, while anti-BoNT/F did not recognize the Adel1 epitope, it did recognize Bdel1. Although anti-BoNT/F showed somewhat less specificity than anti-BoNT/A and BoNT/B, all showed some degree of serotype specificity.
Thus, although the sequence of the BoNT real epitopes are well conserved across the serotypes, they are sufficiently distinct from one another to display differing antibody specificities. BoNT del1 peptides may be used for characterizing, diagnosing, or otherwise distinguishing between BoNT serotypes.
Example 4
Immunogenic Properties of a BoNT Mosaic Antigen
BALB/c mice were vaccinated with fusion proteins carrying multiple BoNT real epitopes, so-called mosaic antigens. Animals were injected with HisbioRAP-BoNT/FBAdel1s (FIG. 7, upper panel) or α-Tox/FBAdel1s (FIG. 7, second panel) over a period, of 4 weeks, and screened for an immune response at 28 and 42 days by direct ELISA.
Immunization with α-Tox/FBAdel1s resulted in a 4-15 fold increase in recognition of the immunogen as compared to pre-immune sera (Table 2). Immunization with HisbioRAP-FBAdel1s resulted in a 30-33 fold increase in recognition of the immunogen as compared to pre-immune sera (Table 2).
Example 5
Serotype Specificity of Anti-BoNT/FBAdel1
As demonstrated in FIGS. 2-4, real epitopes described herein are immunogenic when introduced into a host in the context of the full-length toxin. It is for this reason that antisera raised against BoNT/A, /B, and /F recognize fusion proteins bearing the isolated epitopes. To demonstrate that the epitopes are immunogenic in the context of a fusion protein, a series of BoNT-derived fusions were probed by Western blot with anti-BoNT/A or /B antisera (FIG. 5B-C), or with mouse antisera raised against α-Tox/FBAdel1s, a fusion protein bearing the Adel1, Bdel1, and Fdel1 epitopes (FIG. 7, second panel). BoNT/A-L, BoNT/B-L, and HisbioRAP-BoNT/FBAdel1 were loaded as positive controls. A GFP-BoNT/A-CH fusion was also loaded as a positive control for anti-BoNT/A. HisbioRAP-BoNT-Zn was included as a negative control. Protein resolution was confirmed by Coomassie staining (FIG. 5A) and identical blots were probed with antisera.
Anti-BoNT/A recognized full-length BoNT/A, BoNT/A-CH, and the FBAdel1 fusion protein, but did not recognize full-length BoNT-L (FIG. 5B). Anti-BoNT/B showed similar specificity, recognizing full-length BoNT/B-L and the FBAdel1 fusion, but not BoNT/A-L or BoNT/A-CH (FIG. 5C). Both of these findings are consistent with the high degree of serotype specificity of these antisera demonstrated in FIG. 4. Notably, neither anti-BoNT/A nor anti-BoNT/B recognized tetanus toxin light chain (FIG. 5B-C), despite the fact that it bears a well conserved del1 epitope (FIG. 3). Conversely, the anti-FBAdel1 antisera recognized not only BoNT-A-L, BoNT/B-L, and FBAdel1, it also recognized tetanus toxin light chain (FIG. 5 D) and BoNT/G-L (not shown).
These findings demonstrate several important points. First, the BoNT real epitopes described herein elicit immune responses even when outside the context of the full-length toxin and in the context of a fusion protein. Second, mosaic antigens bearing multiple BoNT real epitopes elicit multiple independent immune responses. Thus, anti-FBAdel1 shows immunoreactivity to BoNT/A-L (FIG. 5B), BoNT/B-L (FIG. 5C), and BoNT/G (not shown). Third, mosaic antigens bearing multiple BoNT real epitopes are more potent immunogens than the full-length toxins, generating a profile of anti-BoNT antibodies that no longer display a high degree of serotype specificity. Thus, anti-FBAdel1 shows immunoreactivity with tetanus toxin whereas anti-BoNT/A and anti-BoNT/B do not.
Example 6
Identification of BoNT Mimetic Epitopes Phage Display
BoNT/A, BoNT/B, and BoNT/E epitope mimetics were isolated from a random peptide display library using a modified biopanning protocol (See Materials and Methods, supra). Twenty-two BoNT/A mimetics were isolated as fusions with phage capsid protein III and VII (Table 3). Seventeen BoNT/B mimetics were isolated as fusions with protein (Table 4). Thirteen BoNT/E mimetics were isolated as fusions with phage capsid protein VII (Table 5).
Example 7
Purification of Anti-BoNT Antibodies with BoNT Mimetic Epitopes
Full-length BoNT heavy and light chains were probed by Western blot with whole anti-BoNT/A antisera (FIG. 6A), or antisera purified against BoNT/AIII-26 (FIG. 6B), BoNT/AIII-1 (FIG. 6C), or BoNT/AIII-L1 (FIG. 6D-E). The AIII-26, AIII-1, and AIII-L1 peptides were loaded as positive controls.
Anti-BoNT/A recognized the BoNT heavy and light chains, but showed no appreciable recognition of the mimetic peptides (FIG. 6A). By contrast, serum purified against the mimetic peptides recognized the BoNT/A light chain, but not the heavy chain (FIG. 6B-E). This confirmed that the mimetic epitopes bind anti-BoNT antibodies that are specific for the light chain. Antibodies purified against BoNT/AIII-1 lost the capacity to recognize the BoNT/A light chain treated with SDS, suggesting that it mimics a structural epitope BoNT/A (FIG. 6D).
Example 8
Immunogenic Properties of BoNT Mimetic Epitopes
Groups of three BALB/c mice were injected with HisbioRAP-BoNT/A-mimetic-8, a fusion protein bearing eight mimetic epitopes in series (FIG. 7, bottom panel). Following a four week injection protocol, animals were challenged with 5×LD50 of BoNT/A. The survival rate of control animals was 0% (0/3), while the survival rate of animals receiving the mimetic peptides was 66% (2/3). Multiple trials of the protocol gave consistent results.
Example 9
Receptor Associated Protein-Enhanced Solubility of BoNT Epitopes
Surprisingly and unexpectedly, use of the RAP carrier peptide consistently produced fusion proteins in soluble form, as compared to other constructs which generated largely insoluble proteins that accumulated in inclusion bodies. Three different carriers were tested: BirA, thioredoxin, and RAP. Only RAP fusion proteins were consistently soluble. Although many of the fusions were identical to each other except for the very short BoNT/A-L region and the carrier portion, the difference in the localization and solubility of the proteins was marked.
Example 10
Clostridium perfringens α-Toxin-Induced Secretion of BoNT Epitope Fusion Proteins
Fusion proteins including Clostridium perfringens α-toxin as the carrier surprisingly and unexpectedly were secreted from the host cell into the culture media. In media collected from E. coli expressing α-Tox-FBAdel1s, the fusion protein was the only high-molecular weight polypeptide present in significant quantities. Thus, using α-toxin as the carrier facilitates and simplifies purification of the fusion proteins.
Example 11
Detection of Anti-BoNT Antibodies in a Sample
The BoNT real and mimetic epitopes described herein may be used to detect anti-BoNT antibodies in a sample. Samples may be prepared for analysis using methods known in the art based on the specific nature of the sample. For example, the sample may be whole or fractionated blood collected from patients or experimental subjects. Antibodies in the sample may be detected through immunoblotting of sample proteins immobilized on a solid substrate. Anti-BoNT antibodies specifically bound to immobilized proteins may be visualized using an appropriate secondary detection reagent such as a species-specific secondary antibody carrying an enzymatic label. Additionally or alternatively, antibodies present in the sample may be detected using an agglutination test, in which a fluid sample is mixed with BoNT fusion proteins and monitored for the appearance of precipitates. Additionally or alternatively, antibodies present in the sample may be detected using affinity chromatography in which the sample is exposed to BoNT fusion proteins coupled to a polymer resin. Bound antibodies may be eluted from the BoNT-resin and detected using an appropriate secondary detection regent. Additionally or alternatively, antibodies present in the sample may be detected by means of an enzyme linked immunosorbant assay (ELISA) or enzyme immunoassay (EIA). BoNT-fusion proteins may be affixed to a surface and exposed to a fluid sample under conditions conducive to antibody-ligand binding. Specifically bound antibodies may be detected using an appropriate secondary detection reagent. In some embodiments, the methods are provided as kits and contain reagents to detect antibodies according to any of the methods described above.
Example 12
Immunization of a Human or Animal Subject Against BoNT Toxicity
BoNT epitopes described herein may be used to vaccinate humans and animals against BoNT neurotoxicity. BoNT epitopes may be fused to a carrier protein and administered to human and animal subjects in the presence of adjuvants such as but not limited to aluminum salts and liposomes. Those skilled, in the art will understand that any number of pharmaceutically acceptable adjuvants can also be used. Carrier proteins having adjuvant properties themselves, such as cholera toxin B, may also be used. To maximize the spectrum of protection, vaccination compositions may include several real or mimetic BoNT epitopes. Real epitopes may be derived, from a single BoNT serotype or several BoNT serotypes. Immunogenic compositions may be administered to a human or animal subjects intramuscularly, subdermally, intranasally, or through any other suitable route. Immunogenic compositions may also take the form of nucleic acid vaccines, in which nucleic acids encoding BoNT epitopes are administered to human or animal subjects. Alternatively, sequences encoding BoNT epitopes may be incorporated into host organisms such as Salmonella for oral or intranasal administration. Administration can be provided as an initial dose, followed by one or more booster doses. Booster doses can be provided a day, two days, three days, a week, two weeks, three weeks, one, two, three, six or twelve months after an initial dose. A booster dose may be administered after an evaluation of the subject's antibody titer.







TABLE 1







Oligonucleotide pairs encoding BoNT light chain epitopes









Designation
Sequence (SEQ ID NOS 1-10, respectively, in order of apperance)
Fusion





Del1-5′
5′-gtacctggatccgttccggttagctattatgatagcacgtatttaagcacctaagcctgca
HisbioRAP-


Del1-3′
5′-ggcttagtgcttaaatacgtgctatcataatagctaaccggaacggatccag
del1s


 


Del4-5′
5′-gtacctggatcctttaatggtcaaaataccgaaattaataatatgaattttaccaaataagcctgca
HisbioRAP-


Del4-3′
5′-ggcttatttggtaaaattcatattattaattcggtattttgaccattaaaggatccag
del4s


 


A-Zn5′
5′-ctggatcccatgaactgattcatgcgggccatcgcctgtatggcattgtcgactaaagcctgca
FlisbioRAP-


A-Zn3′
5′-ggctttagtcgacaatgccatacaggcgatggcccgcatgaatcagttcatgggatccaggtac
A-Zn


 


Fdel1-5′
5′-ctggatccggcagcagcgcgtattatgatccgaactatctgaccaccgtcgactaagcctgca
HisbioRAP-


Fdel1-3′
5′-ggcttagtcgacggtggtcagatagttcggatcataatacgcgctgctgccggatccaggtac
Fdel1s


 


Bdel1-5′
5′-ctggatccgatgtgtgcgaatattatgatccggattatctgaacaccgtcgactaagcctgca
HisbioRAP-


Bdel1-3′
5′-ggcttagtcgacggtgttcagataatccggatcataatattcgcacacatcggatccaggtac
Bdel1s
















TABLE 2







Murine BoNT/FBA-del1-induced immune response.


Results are presented as fold increase in OD450


over pre-immune sera in a direct ELISA.









Animal










A
B









Antigen












α-Tox-
HisbioRAP-
α-Tox-
HisbioRAP-



FBAdel1s
FBAdel1s
FBAdel1s
FBAdel1s















Bleed 1
3.9X
 9.5X
1.3X
4.9X


Bleed 2
2.8X
18.8X
1.3X
9.0X


Bleed 3
 15X
33.7X
4.1X
 30X
















TABLE 3







BoNT/A mimetic epitopes









Designation
Sequence
SEQ ID NO:










Sequences isolated from peptide display 


utilizing protein III









BoNT/AIII-0
IKSNPQTSNEFL
11


BoNT/AIII-1
TAPTMPITTPRL
12


BoNTLAIII-L1
EQPMQHLSGAFA
13


BoNT/AIII-3
TYLQIIPDVGYI
14


BoNT/AIII-6
AIGDINPPHLDT
15


BoNT/AIII-9
VQSSMLPIPSTP
16


BoNT/AIII-24
VQRSTFILPTTP
17


BoNT/AIII-26
DGDINPPTRTML
18


BoNT/AIII-27
IKSNPQTSNEFL
19


 







Sequences isolated from peptide display 


utilizing protein VII









BoNT/AVII1-3
DPTRFHSRPPAI
19


BoNT/AVII1-6
DFGDHNPPEQSS
20


BoNT/AVII1-12
PLHPSQMPLSLI
21


BoNT/AVII1-13
APTSPVTHGPQL
22


BoNT/AVII1-16
QEALGLIVESHT
23


BoNT/AVII1-19
SLTSPITPRPEY
24


BoNT/AVII1-20
DVGDLGRPVHFI
25


BoNT/AVII3-6
WCASVQRPLTLV
26


BoNT/AVII3-7
FGPRSLPDHYYD
27


BoNT/AVII3-13
PTFGRQIPLSVI
28


BoNT/AVII3-17
VGADVGTLSAAF
29


BoNT/AVII5-4
YSYWDSTFLDTL
30


BoNT/AVII5-18
QAPLSLVQPFRD
31
















TABLE 4







BoNT/B mimetic epitopes.


Sequences isolated by peptide display using


protein VII.









Designation
Sequence
SEQ ID NO:





BoNT/BVII-1
GLARRYVLWPVAS
32


 


BoNT/BVII-2
NDQRRVWQAQRC
33


 


BoNT/BVII-3
GLAQRWATAHCW
34


 


BoNT/BVII-4
HARHLWHIASTA
35


 


BoNT/BVII-5
FHHHRYLTCAAA
36


 


BoNT/BVII-6
DGPRHLLRHHAI
37


 


BoNT/BVII-7
GLARRYVLWPVA
38


 


BoNT/BVII-8
DQPRRLYHVTAP
39


 


BoNT/BVII-9
LGHAWSRWHVPI
40


 


BoNT/BVII-10
DVTRRHWSPSPS
41


 


BoNT/BVII-11
RLPHLHPWHYAV
42


 


BoNT/BVII-12
WWRVTHTAQSVS
43


 


BoNT/BVII-13
RWSLHSHHAPKV
44


 


BoNT/BVII-14
AGMWGWRHAHTI
45


 


BoNT/BVII-15
PLHAYFHALKAG
46


 


BoNT/BVII-16
HWRHYNHSQAPV
47


 


BoNT/BVII-17
SRHVFVRHNQHC
48
















TABLE 5







BoNT/E mimetic epitopes.


Sequences isolated by peptide display using


protein VII.









Designation
Sequence
SEQ ID NO:





BoNT/EVII-1
KRVAPPEFGIPI
49


 


BoNT/EVII-2
LRGLPRCCTYAW
50


 


BoNT/EVII-3
HRLPFSFHHSHV
51


 


BoNT/EVII-4
WSPLARLCARSC
52


 


BoNT/EVII-5
WRAGHLAWLHGM
53


 


BoNT/EVII-6
AHRRAFHGAHHV
54


 


BoNT/EVII-7
HHPFPTPVLLLC
55


 


BoNT/EVII-8
HVHRPFGHTHPP
56


 


BoNT/EVII-9
HHHFLHRSPSTV
57


 


BoNT/EVII-10
PDRYSGPFTNVY
58


 


BoNT/EVII-11
YRVAPPPGLMAN
59


 


BoNT/EVII-12
TLARRHMLINTF
60


 


BoNT/EVII-13
LRHWHCPTKLQT
61
















TABLE 6







RAP-binding peptides isolated by phage display.









Designation
Sequence
SEQ ID NO:





RAP-bp1
APAWRAPAQQLG
62


 


RAP-bp2
HLALHAHLHHLL
63


 


RAP-bp3
PHLWFHGFLELC
64


 


RAP-bp4
PLRLAPLLCYVK
65
















TABLE 7







Nickel-binding peptides identified by phage


display.









Designation
Sequence
SEQ ID NO:





Ni-bp1
HPGRPHHAHRHH
66


 


Ni-bp2
HTHHPVHRATPE
67


 


Ni-bpi
PHSHEHHSARLD
68


 


Ni-bp4
HRHLVKHRELSP
69


 


Ni-bp5
RDHRVTASHHRH
70


 


Ni-bp6
DLPRRAHHSRPC
71


 


Ni-bp7
ARRHHHTPPALH
72


 


Ni-bp8
PGPRRVHHHTTS
73


 


Ni-bp9
STGHSRYHGHHR
74


 


Ni-bp10
ADFRRAHAHPPR
75


 


Ni-bp11
PRRHHDHSPPRI
76


 


Ni-bp12
DTSRRHHRPPVH
77


 


Ni-bp13
PHQCLPPHHARF
78


 


Ni-bp14
IPPHHHHSTNTR
79


 


Ni-bp15
HRPHGSLGHPKL
80


 


Ni-bp16
TLPHHAQRAPYH
81


 


Ni-bp17
PPSKTAPHHRVH
82


 


Ni-bp18
PLHHHPTRAPLT
83


 


Ni-bp19
AHHAHPPRPALS
84


 


Ni-bp20
GAHHIPKHDHVA
85


 


Ni-bp21
TTAHPIHAPCSR
86


 


Ni-bp22
PLHHHPTRAPLT
87
















TABLE 8







Streptavidin-binding peptides isolated by phage


display.









Designation
Sequence
SEQ ID NO:





SA-bp1
VIWSHPQNYTIGS
88


 


SA-bp2
SFDRFLATGAMY
89


 


SA-bp3
PGPDCATYPFCN
90


 


SA-bp4
WHPQSGLTPCTI
91

## Claims

1. An antigenic composition comprising: a fusion protein comprising a carrier peptide and at least one epitope, wherein the carrier peptide is selected from the group consisting of Receptor Associated Protein (RAP) and Clostridium perfringens α-toxin, and wherein the epitope comprises a botulinum neurotoxin (BoNT) epitope or a mimetic BoNT epitope capable of eliciting an immune response in a human or animal subject.

2. The composition of claim 1, wherein the fusion protein specifically binds to an anti-BoNT antibody.

3. The composition of claim 1, wherein the BoNT epitope is selected from the group consisting of SEQ ID NOs: 19, 20, 22, 24, 25, 29, 30, 31, 102 and 118.

4. The composition of claim 1 further comprising: multiple BoNT epitopes and/or multiple mimetic BoNT epitopes.

5. The composition of claim 4, wherein the BoNT epitopes and/or mimetic BoNT epitopes are selected from the group consisting of SEQ ID NOs: 11-61 and 102-133.

6. A method for producing an antigenic composition comprising:
(a) expressing in a host cell a fusion protein comprising a carrier peptide and at least one epitope, wherein the carrier peptide is selected from the group consisting of Receptor Associated Protein (RAP) and Clostridium perfringens α-toxin; and
(b) isolating the fusion protein produced by the host,
wherein the epitope comprises a botulinum neurotoxin (BoNT) epitope or a mimetic BoNT epitope capable of eliciting an immune response in a human or animal subject.

7. The method of claim 6, wherein the BoNT epitope is selected from the group consisting of SEQ ID NOs: 11-61 and 102-133.

8. The method of claim 6, wherein the fusion protein is expressed in the host cell from an expression vector.

9. The method of claim 8, wherein the expression vector is selected from the group consisting of a plasmid DNA, a viral vector, a bacterial vector, a mammalian vector, and a vector capable of integrating into the genome of the host cell.

10. The method of claim 6, wherein the fusion protein comprises a carrier peptide and multiple BoNT epitopes and/or multiple mimetic BoNT epitopes.

11. The method of claim 10, wherein the BoNT epitopes are selected from the group consisting of SEQ ID NOs: 11-61 and 102-133.